vs
Privia Health Group, Inc.（PRVA）与Strata Critical Medical, Inc.（SRTA）财务数据对比。点击上方公司名可切换其他公司
Privia Health Group, Inc.的季度营收约是Strata Critical Medical, Inc.的23.8倍（$541.2M vs $22.7M）。Strata Critical Medical, Inc.同比增速更快（361.2% vs 17.4%）。过去两年Privia Health Group, Inc.的营收复合增速更高（14.2% vs -33.6%）
Privia Health Group, Inc.是总部位于美国的医疗科技与服务企业，为独立诊所、医疗系统和医疗支付方提供价值导向型医疗解决方案，涵盖人群健康管理、患者互动平台、护理协调支持及行政流程优化工具，助力提升诊疗效果、降低医疗参与方运营成本。
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
PRVA vs SRTA — 直观对比
营收规模更大
PRVA
是对方的23.8倍
$22.7M
营收增速更快
SRTA
高出343.8%
17.4%
两年增速更快
PRVA
近两年复合增速
-33.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $541.2M | $22.7M |
| 净利润 | $9.2M | — |
| 毛利率 | — | -0.9% |
| 营业利润率 | 2.1% | -18.4% |
| 净利率 | 1.7% | — |
| 营收同比 | 17.4% | 361.2% |
| 净利润同比 | 108.0% | — |
| 每股收益（稀释后） | $0.08 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRVASRTA
| Q4 25 | $541.2M | $22.7M | ||
| Q3 25 | $580.4M | $49.3M | ||
| Q2 25 | $521.2M | $70.8M | ||
| Q1 25 | $480.1M | $54.3M | ||
| Q4 24 | $460.9M | $-8.7M | ||
| Q3 24 | $437.9M | $36.1M | ||
| Q2 24 | $422.3M | $67.9M | ||
| Q1 24 | $415.2M | $51.5M |
净利润PRVASRTA
| Q4 25 | $9.2M | — | ||
| Q3 25 | $6.9M | $57.4M | ||
| Q2 25 | $2.7M | $-3.7M | ||
| Q1 25 | $4.2M | $-3.5M | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $3.5M | $-2.0M | ||
| Q2 24 | $3.5M | $-11.3M | ||
| Q1 24 | $3.0M | $-4.2M |
毛利率PRVASRTA
| Q4 25 | — | -0.9% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 25.1% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 19.7% |
营业利润率PRVASRTA
| Q4 25 | 2.1% | -18.4% | ||
| Q3 25 | 2.5% | -11.4% | ||
| Q2 25 | 0.6% | -7.0% | ||
| Q1 25 | 1.1% | -14.0% | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 1.3% | -19.7% | ||
| Q2 24 | 1.2% | -17.9% | ||
| Q1 24 | 0.2% | -19.2% |
净利率PRVASRTA
| Q4 25 | 1.7% | — | ||
| Q3 25 | 1.2% | 116.5% | ||
| Q2 25 | 0.5% | -5.3% | ||
| Q1 25 | 0.9% | -6.4% | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 0.8% | -5.4% | ||
| Q2 24 | 0.8% | -16.7% | ||
| Q1 24 | 0.7% | -8.2% |
每股收益（稀释后）PRVASRTA
| Q4 25 | $0.08 | $-0.11 | ||
| Q3 25 | $0.05 | $0.70 | ||
| Q2 25 | $0.02 | $-0.05 | ||
| Q1 25 | $0.03 | $-0.04 | ||
| Q4 24 | $0.03 | $-0.11 | ||
| Q3 24 | $0.03 | $-0.03 | ||
| Q2 24 | $0.03 | $-0.15 | ||
| Q1 24 | $0.02 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $479.7M | $31.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $737.2M | $279.1M |
| 总资产 | $1.4B | $325.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRVASRTA
| Q4 25 | $479.7M | $31.0M | ||
| Q3 25 | $441.4M | $22.8M | ||
| Q2 25 | $390.1M | $58.8M | ||
| Q1 25 | $469.3M | $34.8M | ||
| Q4 24 | $491.1M | $18.4M | ||
| Q3 24 | $422.0M | $20.0M | ||
| Q2 24 | $387.4M | $26.3M | ||
| Q1 24 | $351.1M | $36.8M |
股东权益PRVASRTA
| Q4 25 | $737.2M | $279.1M | ||
| Q3 25 | $709.1M | $283.0M | ||
| Q2 25 | $682.9M | $223.1M | ||
| Q1 25 | $659.4M | $219.7M | ||
| Q4 24 | $635.2M | $221.9M | ||
| Q3 24 | $614.9M | $233.5M | ||
| Q2 24 | $595.4M | $229.4M | ||
| Q1 24 | $576.8M | $236.6M |
总资产PRVASRTA
| Q4 25 | $1.4B | $325.5M | ||
| Q3 25 | $1.4B | $335.1M | ||
| Q2 25 | $1.3B | $257.9M | ||
| Q1 25 | $1.2B | $250.6M | ||
| Q4 24 | $1.1B | $256.7M | ||
| Q3 24 | $1.1B | $282.9M | ||
| Q2 24 | $1.1B | $280.3M | ||
| Q1 24 | $1.0B | $282.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $127.5M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-10.2M |
| 自由现金流率自由现金流/营收 | — | -44.7% |
| 资本支出强度资本支出/营收 | — | 8.1% |
| 现金转化率经营现金流/净利润 | 13.93× | — |
| 过去12个月自由现金流最近4个季度 | — | $-58.5M |
8季度趋势，按日历期对齐
经营现金流PRVASRTA
| Q4 25 | $127.5M | $-8.3M | ||
| Q3 25 | $52.0M | $-37.3M | ||
| Q2 25 | $8.0M | $-3.1M | ||
| Q1 25 | $-24.1M | $-246.0K | ||
| Q4 24 | $74.8M | $-1.8M | ||
| Q3 24 | $33.2M | $6.4M | ||
| Q2 24 | $34.5M | $8.4M | ||
| Q1 24 | $-33.1M | $-15.6M |
自由现金流PRVASRTA
| Q4 25 | — | $-10.2M | ||
| Q3 25 | — | $-40.1M | ||
| Q2 25 | — | $-5.4M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $-6.3M | ||
| Q3 24 | — | $-3.0M | ||
| Q2 24 | — | $-7.7M | ||
| Q1 24 | — | $-16.4M |
自由现金流率PRVASRTA
| Q4 25 | — | -44.7% | ||
| Q3 25 | — | -81.4% | ||
| Q2 25 | — | -7.6% | ||
| Q1 25 | — | -5.3% | ||
| Q4 24 | — | 72.7% | ||
| Q3 24 | — | -8.2% | ||
| Q2 24 | — | -11.4% | ||
| Q1 24 | — | -31.8% |
资本支出强度PRVASRTA
| Q4 25 | — | 8.1% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | -52.6% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 23.8% | ||
| Q1 24 | — | 1.6% |
现金转化率PRVASRTA
| Q4 25 | 13.93× | — | ||
| Q3 25 | 7.58× | -0.65× | ||
| Q2 25 | 2.97× | — | ||
| Q1 25 | -5.70× | — | ||
| Q4 24 | 17.00× | — | ||
| Q3 24 | 9.38× | — | ||
| Q2 24 | 9.94× | — | ||
| Q1 24 | -11.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRVA
| FFS Patient Care | $364.4M | 67% |
| Capitated Revenue | $71.4M | 13% |
| Shared Savings | $46.9M | 9% |
| FFS Administrative Services | $36.0M | 7% |
| Care Management Fee PMPM | $20.0M | 4% |
| Other Revenue | $2.5M | 0% |
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
